Adrian V Lee

List of Publications by Year
in descending order

172 papers	12,152 citations	26610 56 h-index	30894 102 g-index
187 all docs	187 docs citations	187 times ranked	17396 citing authors

#	Article	IF	Citations
1	MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer. Molecular Cancer Research, 2022, 20, 373-386.	1.5	7
2	Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. The Lancet Healthy Longevity, 2022, 3, e54-e66.	2.0	9
3	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. Nature Communications, 2022, 13, 514.	5.8	38
4	Hotspot *ESR1* Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Research, 2022, 82, 1321-1339.	0.4	30
5	Semi-deconvolution of bulk and single-cell RNA-seq data with application to metastatic progression in breast cancer. Bioinformatics, 2022, 38, i386-i394.	1.8	0
6	ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nature Communications, 2022, 13, 2011.	5.8	29
7	Isoforms of Neuropilin-2 Denote Unique Tumor-Associated Macrophages in Breast Cancer. Frontiers in Immunology, 2022, 13, .	2.2	4
8	Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. Npj Breast Cancer, 2022, 8, 62.	2.3	10
9	Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. Molecular Cancer Research, 2022, 20, 1405-1419.	1.5	7
10	Identifying Genomic Alterations in Patients With Stage IV Breast Cancer Using MammaSeq: An International Collaborative Study. Clinical Breast Cancer, 2021, 21, 210-217.	1.1	4
11	Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. Cancer Research, 2021, 81, 268-281.	0.4	28
12	Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. Oncogene, 2021, 40, 1318-1331.	2.6	10
13	Exosomes in Breast Cancer â€" Mechanisms of Action and Clinical Potential. Molecular Cancer Research, 2021, 19, 935-945.	1.5	18
14	Abstract PS17-31: Investigating the estrogen receptor Y537S mutation in transgenic models of luminal B breast cancer. , 2021, , .		2
15	Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptorâ€"Positive Breast Cancer. JAMA Network Open, 2021, 4, e216322.	2.8	15
16	A Novel Mouse Model for SNP in Steroid Receptor Co-Activator-1 Reveals Role in Bone Density and Breast Cancer Metastasis. Endocrinology, 2021, 162, .	1.4	5
17	Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells. PLoS Computational Biology, 2021, 17, e1009125.	1.5	3
18	Prognostic factors and survival of patients undergoing surgical intervention for breast cancer bone metastases. Journal of Bone Oncology, 2021, 29, 100363.	1.0	4

#	Article	IF	Citations
19	Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences. Breast Cancer Research, 2021, 23, 1.	2.2	43
20	A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration. Journal of Personalized Medicine, 2021, 11, 1031.	1.1	18
21	Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Research, 2021, 81, 6259-6272.	0.4	10
22	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. Cancers, 2021, 13, 5396.	1.7	17
23	The Development and Implementation of an Autopsy/ Tissue Donation for Breast Cancer Research. New Bioethics, 2021, 27, 349-361.	0.5	1
24	Molecular Biology Information Service: an innovative medical library-based bioinformatics support service for biomedical researchers. Briefings in Bioinformatics, 2020, 21, 876-884.	3.2	4
25	Neural Network Deconvolution Method for Resolving Pathway-Level Progression of Tumor Clonal Expression Programs With Application to Breast Cancer Brain Metastases. Frontiers in Physiology, 2020, 11, 1055.	1.3	3
26	Robust and accurate deconvolution of tumor populations uncovers evolutionary mechanisms of breast cancer metastasis. Bioinformatics, 2020, 36, i407-i416.	1.8	7
27	Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma. Scientific Reports, 2020, 10, 11487.	1.6	16
28	Differential Regulation and Targeting of Estrogen Receptor Î± Turnover in Invasive Lobular Breast Carcinoma. Endocrinology, 2020, 161, .	1.4	17
29	Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology. Breast Cancer Research, 2020, 22, 70.	2.2	15
30	IGF1R constitutive activation expands luminal progenitors and influences lineage differentiation during breast tumorigenesis. Developmental Biology, 2020, 463, 77-87.	0.9	12
31	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. Journal of the National Cancer Institute, 2019, 111, 388-398.	3.0	81
32	Systematic discovery of the functional impact of somatic genome alterations in individual tumors through tumor-specific causal inference. PLoS Computational Biology, 2019, 15, e1007088.	1.5	31
33	FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. Npj Breast Cancer, 2019, 5, 19.	2.3	46
34	Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. , 2019, 7, 265.		68
35	Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Letters, 2019, 461, 21-30.	3.2	18
36	Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis. Clinical Cancer Research, 2019, 25, 3479-3485.	3.2	29

#	Article	IF	Citations
37	Targeted mutation detection in breast cancer using MammaSeqâ„¢. Breast Cancer Research, 2019, 21, 22.	2.2	28
38	Network-guided prediction of aromatase inhibitor response in breast cancer. PLoS Computational Biology, 2019, 15, e1006730.	1.5	5
39	Intratumor Heterogeneity. , 2019, , 17-30.		1
40	Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Molecular Cancer Research, 2019, 17, 457-468.	1.5	29
41	Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. Journal of Neuro-Oncology, 2019, 141, 1-12.	1.4	30
42	The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis. Journal of Neuro-Oncology, 2019, 142, 1-10.	1.4	31
43	Phylogenies Derived from Matched Transcriptome Reveal the Evolution of Cell Populations and Temporal Order of Perturbed Pathways in Breast Cancer Brain Metastases. Lecture Notes in Computer Science, 2019, , 3-28.	1.0	3
44	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	13.5	2,277
45	Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. Journal of Biological Chemistry, 2018, 293, 3700-3709.	1.6	12
46	Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Annals of Oncology, 2018, 29, 872-880.	0.6	73
47	The CARMA3â€"Bcl10â€"MALT1 Signalosome Drives NFÎºB Activation and Promotes Aggressiveness in Angiotensin II Receptorâ€"Positive Breast Cancer. Cancer Research, 2018, 78, 1225-1240.	0.4	65
48	Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes. Oncology, 2018, 94, 176-189.	0.9	20
49	Expression of reactive species related genes is associated with patient survival in luminal B breast cancer. Free Radical Biology and Medicine, 2018, 120, 170-180.	1.3	13
50	Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells. Endocrinology, 2018, 159, 285-296.	1.4	32
51	Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. Scientific Reports, 2018, 8, 17313.	1.6	22
52	Loss of E-cadherin Enhances IGF1â€"IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. Clinical Cancer Research, 2018, 24, 5165-5177.	3.2	58
53	Circulating Tumor Cell Phenotyping via Highâ€"Throughput Acoustic Separation. Small, 2018, 14, e1801131.	5.2	115
54	Precision Medicine in Hormone Receptor-Positive Breast Cancer. Frontiers in Oncology, 2018, 8, 144.	1.3	32

#	Article	IF	Citations
55	Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. Scientific Reports, 2018, 8, 7205.	1.6	71
56	Abstract 3287: An integrated TCGA pan-cancer clinical data resource to drive high quality survival outcome analytics. Cancer Research, 2018, 78, 3287-3287.	0.4	49
57	Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. JCI Insight, 2018, 3, .	2.3	21
58	Integration of cancer registry data into the text information extraction system: Leveraging the structured data import tool. Journal of Pathology Informatics, 2018, 9, 47.	0.8	8
59	Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 392-398.	0.6	7
60	The Cellular Origin and Evolution of Breast Cancer. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a027128.	2.9	67
61	Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. Clinical Cancer Research, 2017, 23, 3802-3812.	3.2	43
62	*THADA* fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2307-2312.	3.3	58
63	Spatial Statistics for Segmenting Histological Structures in H&E Stained Tissue Images. IEEE Transactions on Medical Imaging, 2017, 36, 1522-1532.	5.4	20
64	Intrinsic Subtype Switching and Acquired *ERBB2*/*HER2* Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncology, 2017, 3, 666.	3.4	135
65	New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. Clinical Cancer Research, 2017, 23, 1126-1131.	3.2	11
66	Platform for Quantitative Evaluation of Spatial Intratumoral Heterogeneity in Multiplexed Fluorescence Images. Cancer Research, 2017, 77, e71-e74.	0.4	19
67	Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Research, 2017, 19, 60.	2.2	116
68	Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight, 2017, 2, .	2.3	111
69	Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. Oncotarget, 2017, 8, 66901-66911.	0.8	40
70	Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification. Cureus, 2017, 9, e1434.	0.2	12
71	Genetic Background Influences Patterning and Implementation of Stereotypy in the Early Postnatal Mammary Ductal Tree. FASEB Journal, 2017, 31, 896.10.	0.2	0
72	Restraint and Social Isolation Stressors Differentially Regulate Adaptive Immunity and Tumor Angiogenesis in a Breast Cancer Mouse Model. Cancer and Clinical Oncology, 2016, 6, 12.	0.2	27

#	Article	IF	Citations
73	TCGA Expedition: A Data Acquisition and Management System for TCGA Data. PLoS ONE, 2016, 11, e0165395.	1.1	62
74	Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. Clinical Cancer Research, 2016, 22, 5362-5369.	3.2	73
75	Forkhead Box Q1 Is a Novel Target of Breast Cancer Stem Cell Inhibition by Diallyl Trisulfide. Journal of Biological Chemistry, 2016, 291, 13495-13508.	1.6	56
76	The Endocrine Society Centennial: 40 Years of Aromatase Inhibitors as Targeted Therapy for Breast Cancer. Endocrinology, 2016, 157, 3697-3698.	1.4	0
77	Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability. Endocrinology, 2016, 157, 3760-3766.	1.4	50
78	Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways. Molecular and Cellular Proteomics, 2016, 15, 3045-3057.	2.5	22
79	Epigenomic Deconvolution of Breast Tumors Reveals Metabolic Coupling between Constituent Cell Types. Cell Reports, 2016, 17, 2075-2086.	2.9	84
80	Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations. Cancer Research, 2016, 76, 6785-6794.	0.4	3
81	WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Research, 2016, 18, 92.	2.2	56
82	Non-coding single nucleotide variants affecting estrogen receptor binding and activity. Genome Medicine, 2016, 8, 128.	3.6	5
83	Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer. Cell Communication and Signaling, 2016, 14, 25.	2.7	9
84	High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecologic Oncology, 2016, 141, 348-356.	0.6	20
85	Comprehensive evaluation of fusion transcript detection algorithms and a meta-caller to combine top performing methods in paired-end RNA-seq data. Nucleic Acids Research, 2016, 44, e47-e47.	6.5	141
86	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 1130-1137.	3.2	166
87	Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. PLoS ONE, 2016, 11, e0150564.	1.1	13
88	Pointwise mutual information quantifies intratumor heterogeneity in tissue sections labeled with multiple fluorescent biomarkers. Journal of Pathology Informatics, 2016, 7, 47.	0.8	18
89	Scaffold attachment factor B2 (SAFB2) null mice reveal non-redundant functions compared to its paralog SAFB1. DMM Disease Models and Mechanisms, 2015, 8, 1121-7.	1.2	6
90	Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Frontiers in Endocrinology, 2015, 6, 59.	1.5	152

#	Article	IF	Citations
91	Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Medicine, 2015, 4, 989-994.	1.3	61
92	The center for causal discovery of biomedical knowledge from big data. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 1132-1136.	2.2	30
93	MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years. Journal of the National Cancer Institute, 2015, 107, djv073-djv073.	3.0	189
94	A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. Hormones and Cancer, 2015, 6, 214-224.	4.9	30
95	Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of *Igf1r* That Persists Long after Parturition. Cancer Prevention Research, 2015, 8, 1000-1009.	0.7	16
96	Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. Breast Cancer Research and Treatment, 2015, 153, 311-321.	1.1	20
97	The molecular landscape of premenopausal breast cancer. Breast Cancer Research, 2015, 17, 104.	2.2	56
98	The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor. Molecular and Cellular Endocrinology, 2015, 415, 76-86.	1.6	13
99	Expression of high affinity folate receptor in breast cancer brain metastasis. Oncotarget, 2015, 6, 30327-30333.	0.8	12
100	Identifying and Quantifying Heterogeneity in High Content Analysis: Application of Heterogeneity Indices to Drug Discovery. PLoS ONE, 2014, 9, e102678.	1.1	50
101	Epigenetic Reprogramming of *HOXC10* in Endocrine-Resistant Breast Cancer. Science Translational Medicine, 2014, 6, 229ra41.	5.8	72
102	Genomics, drug approval, and optimal treatment duration. Nature Reviews Clinical Oncology, 2014, 11, 71-72.	12.5	5
103	The evolving role of multi-gene tests in breast cancer management. Oncology, 2013, 27, 210, 212, 214.	0.4	1
104	Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity. Journal of Cellular Biochemistry, 2012, 113, 110-121.	1.2	22
105	Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Research and Treatment, 2012, 132, 61-73.	1.1	39
106	Targeting the Insulin-like Growth Factor Receptor: Developing Biomarkers from Gene Expression Profiling. Critical Reviews in Oncogenesis, 2012, 17, 161-173.	0.2	50
107	Long-range massively parallel mate pair sequencing detects distinct mutations and similar patterns of structural mutability in two breast cancer cell lines. Cancer Genetics, 2011, 204, 447-457.	0.2	16
108	High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy. Clinical Cancer Research, 2011, 17, 2314-2327.	3.2	112

#	Article	IF	Citations
109	The IGF Pathway Regulates ERα through a S6K1-Dependent Mechanism in Breast Cancer Cells. Molecular Endocrinology, 2011, 25, 516-528.	3.7	99
110	Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. Journal of Clinical Investigation, 2011, 121, 212-225.	3.9	114
111	Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Research and Treatment, 2010, 123, 651-660.	1.1	21
112	Serine–derivatized gadonanotubes as magnetic nanoprobes for intracellular labeling. Contrast Media and Molecular Imaging, 2010, 5, 34-38.	0.4	23
113	Sustained c-Jun-NH2-Kinase Activity Promotes Epithelial-Mesenchymal Transition, Invasion, and Survival of Breast Cancer Cells by Regulating Extracellular Signal-Regulated Kinase Activation. Molecular Cancer Research, 2010, 8, 266-277.	1.5	70
114	Parity-Induced Decrease in Systemic Growth Hormone Alters Mammary Gland Signaling: A Potential Role in Pregnancy Protection from Breast Cancer. Cancer Prevention Research, 2010, 3, 312-321.	0.7	15
115	Histone Deacetylase 7 and FoxA1 in Estrogen-Mediated Repression of RPRM. Molecular and Cellular Biology, 2010, 30, 399-412.	1.1	67
116	Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition. Clinical Cancer Research, 2010, 16, 4654-4665.	3.2	58
117	A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Research, 2009, 19, 167-177.	2.4	111
118	BMS-536924 Reverses IGF-IR-Induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of MCF7 Cells. Clinical Cancer Research, 2009, 15, 226-237.	3.2	43
119	Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases. Cancer Cell, 2009, 15, 539-550.	7.7	332
120	Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Research and Treatment, 2009, 114, 287-299.	1.1	94
121	Insulin Receptor Substrates (IRSs) and Breast Tumorigenesis. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 415-422.	1.0	66
122	Altered mammary gland development in the p53+/m mouse, a model of accelerated aging. Developmental Biology, 2008, 313, 130-141.	0.9	29
123	The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Frontiers in Bioscience - Landmark, 2008, Volume, 3273.	3.0	108
124	Progesterone Receptor-B Regulation of Insulin-Like Growth Factor–Stimulated Cell Migration in Breast Cancer Cells via Insulin Receptor Substrate-2. Molecular Cancer Research, 2008, 6, 1491-1498.	1.5	21
125	Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer Prognosis. Journal of Clinical Oncology, 2008, 26, 4078-4085.	0.8	238
126	Novel egg white–based 3-D cell culture system. BioTechniques, 2008, 45, 165-171.	0.8	45

#	Article	IF	Citations
127	Oncogenic Transformation by the Signaling Adaptor Proteins Insulin Receptor Substrate (IRS)-1 and IRS-2. Cell Cycle, 2007, 6, 705-713.	1.3	154
128	Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-Î²B and Snail. Molecular and Cellular Biology, 2007, 27, 3165-3175.	1.1	219
129	Decreased lactation capacity and altered milk composition in insulin receptor substrate null mice is associated with decreased maternal body mass and reduced insulin-dependent phosphorylation of mammary Akt. Journal of Endocrinology, 2007, 194, 327-336.	1.2	24
130	Crosstalk between the p190-B RhoGAP and IGF signaling pathways is required for embryonic mammary bud development. Developmental Biology, 2007, 309, 137-149.	0.9	38
131	Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Molecular and Cellular Endocrinology, 2007, 277, 13-25.	1.6	32
132	Gene expression profiling reveals novel regulation by bisphenol-A in estrogen receptor-Î±-positive human cells. Environmental Research, 2006, 100, 86-92.	3.7	60
133	Novel role of the RET finger protein in estrogen receptor-mediated transcription in MCF-7 cells. Biochemical and Biophysical Research Communications, 2006, 349, 540-548.	1.0	17
134	Crystal Structure of the SH3 Domain of Î²PIX in Complex with a High Affinity Peptide from PAK2. Journal of Molecular Biology, 2006, 358, 509-522.	2.0	45
135	The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Research and Treatment, 2006, 98, 315-327.	1.1	88
136	Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nature Clinical Practice Oncology, 2006, 3, 134-135.	4.3	0
137	Epidermal Growth Factor Induces Insulin Receptor Substrate-2 in Breast Cancer Cells via c-Jun NH2-Terminal Kinase/Activator Protein-1 Signaling to Regulate Cell Migration. Cancer Research, 2006, 66, 5304-5313.	0.4	72
138	Disruption of Scaffold Attachment Factor B1 Leads to TBX2 Up-regulation, Lack of p19ARF Induction, Lack of Senescence, and Cell Immortalization. Cancer Research, 2006, 66, 7859-7863.	0.4	17
139	Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptorâ€"Positive Breast Cancer. Clinical Cancer Research, 2006, 12, 1013s-1018s.	3.2	54
140	Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. Journal of Endocrinology, 2006, 191, 605-612.	1.2	96
141	Mammary Tumorigenesis and Metastasis Caused by Overexpression of Insulin Receptor Substrate 1 (IRS-1) or IRS-2. Molecular and Cellular Biology, 2006, 26, 9302-9314.	1.1	152
142	GLUT4 Distribution between the Plasma Membrane and the Intracellular Compartments Is Maintained by an Insulin-modulated Bipartite Dynamic Mechanism. Journal of Biological Chemistry, 2006, 281, 484-490.	1.6	74
143	The WT1 Wilmsâ€™ tumor suppressor gene product interacts with estrogen receptor-Î± and regulates IGF-I receptor gene transcription in breast cancer cells. Journal of Molecular Endocrinology, 2005, 35, 135-144.	1.1	33
144	Estrogen Receptorâ€"Positive, Progesterone Receptorâ€"Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance. Journal of the National Cancer Institute, 2005, 97, 1254-1261.	3.0	423

#	Article	IF	Citations
145	Overexpression of Des(1–3) Insulin-Like Growth Factor 1 in the Mammary Glands of Transgenic Mice Delays the Loss of Milk Production with Prolonged Lactation1. Biology of Reproduction, 2005, 73, 1116-1125.	1.2	20
146	Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor. Cancer Research, 2005, 65, 3781-3787.	0.4	185
147	Scaffold Attachment Factor B1 Functions in Development, Growth, and Reproduction. Molecular and Cellular Biology, 2005, 25, 2995-3006.	1.1	47
148	Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy. Journal of Clinical Oncology, 2005, 23, 7721-7735.	0.8	430
149	A Dominant Negative Type I Insulin-like Growth Factor Receptor Inhibits Metastasis of Human Cancer Cells. Journal of Biological Chemistry, 2004, 279, 5017-5024.	1.6	142
150	Increases in estrogen receptorα concentration in breast cancer cells promote serine 118/104/106–independent AF–1 transactivation and growth in the absence of estrogen. FASEB Journal, 2004, 18, 81-93.	0.2	69
151	Structure-Function Analysis of the Estrogen Receptor α Corepressor Scaffold Attachment Factor-B1. Journal of Biological Chemistry, 2004, 279, 26074-26081.	1.6	56
152	AIB1/SRC-3 Deficiency Affects Insulin-Like Growth Factor I Signaling Pathway and Suppresses v-Ha-ras-induced Breast Cancer Initiation and Progression in Mice. Cancer Research, 2004, 64, 1875-1885.	0.4	178
153	Bisphenol-A and estradiol exert novel gene regulation in human MCF-7 derived breast cancer cells. Molecular and Cellular Endocrinology, 2004, 221, 47-55.	1.6	37
154	Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene, 2003, 22, 6937-6941.	2.6	47
155	Local Insulin-Like Growth Factor-II Mediates Prolactin-Induced Mammary Gland Development. Molecular Endocrinology, 2003, 17, 460-471.	3.7	91
156	SAFB2, a New Scaffold Attachment Factor Homolog and Estrogen Receptor Corepressor. Journal of Biological Chemistry, 2003, 278, 20059-20068.	1.6	76
157	Insulin-Like Growth Factor-I Inhibits Progesterone Receptor Expression in Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway: Progesterone Receptor as a Potential Indicator of Growth Factor Activity in Breast Cancer. Molecular Endocrinology, 2003, 17, 575-588.	3.7	207
158	Cross Talk Between Estrogen Receptor and IGF Signaling in Normal Mammary Gland Development and Breast Cancer1. Breast Disease, 2003, 17, 105-114.	0.4	23
159	New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. Clinical Cancer Research, 2003, 9, 516S-23S.	3.2	10
160	Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Research, 2003, 63, 5203-8.	0.4	75
161	Disruption of Steroid and Prolactin Receptor Patterning in the Mammary Gland Correlates with a Block in Lobuloalveolar Development. Molecular Endocrinology, 2002, 16, 2675-2691.	3.7	105
162	Activation of renal signaling pathways in db/db mice with type 2 diabetes. Kidney International, 2001, 60, 495-504.	2.6	94

#	Article	IF	Citations
163	Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats. Carcinogenesis, 2001, 22, 2039-2047.	1.3	42
164	Crosstalk between the insulin-like growth factors and estrogens in breast cancer. Journal of Mammary Gland Biology and Neoplasia, 2000, 5, 107-115.	1.0	210
165	Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3â€²-Kinase Inhibition. Molecular and Cellular Biology, 2000, 20, 1489-1496.	1.1	113
166	Tamoxifen-Bound Estrogen Receptor (ER) Strongly Interacts with the Nuclear Matrix Protein HET/SAF-B, a Novel Inhibitor of ER-Mediated Transactivation. Molecular Endocrinology, 2000, 14, 369-381.	3.7	89
167	Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo. Molecular Endocrinology, 1999, 13, 787-796.	3.7	292
168	Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo. Molecular Endocrinology, 1999, 13, 787-796.	3.7	81
169	Igf system components as prognostic markers in breast cancer. Breast Cancer Research and Treatment, 1998, 47, 295-302.	1.1	70
170	Cloning, Chromosome Localization, Expression, and Characterization of an Src Homology 2 and Pleckstrin Homology Domain-containing Insulin Receptor Binding Protein hGrb10Î³. Journal of Biological Chemistry, 1997, 272, 29104-29112.	1.6	69
171	Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Molecular and Cellular Endocrinology, 1994, 99, 211-220.	1.6	62
172	Inability of Overexpressed des(1â€"3)Human Insulin-Like Growth Factor I (IGF-I) to Inhibit Forced Mammary Gland Involution Is Associated with Decreased Expression of IGF Signaling Molecules. , 0, .		8